Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface and/or that enhance the activity of GLP-1, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent and diagnose a condition/disease associated with neurodegenerative diseases or a related clinical condition thereof, are disclosed.

The present invention relates to a bowel cleansing composition comprising polyethylene glycol and ascorbate ingredients, the bowel cleansing composition of the present invention being easier to take, while having an excellent bowel cleansing effect, thereby being usable as an effective bowel cleansing agent.

The present invention relates to a bowel cleansing composition comprising polyethylene glycol and ascorbate ingredients, the bowel cleansing composition of the present invention being easier to take, while having an excellent bowel cleansing effect, thereby being usable as an effective bowel cleansing agent.

Disclosed are compositions comprising a polyene macrolide antibiotic and an azole antifungal, and packaged pharmaceutical products comprising the disclosed compositions. Also disclosed are methods of treating systemic fungal infections comprising co-administering to a mammal a polyene macrolide antibiotic and an azole antifungal (conjoint administration). The co-administration may be simultaneous (e.g., in a single formulation or in separate formulations), sequential, or staggered.

Disclosed are compositions comprising a polyene macrolide antibiotic and an azole antifungal, and packaged pharmaceutical products comprising the disclosed compositions. Also disclosed are methods of treating systemic fungal infections comprising co-administering to a mammal a polyene macrolide antibiotic and an azole antifungal (conjoint administration). The co-administration may be simultaneous (e.g., in a single formulation or in separate formulations), sequential, or staggered.

The present invention relates to extended release microparticles comprising a drug, and a preparation method therefor, and when the extended release microparticles comprising a drug are administered in order to replace conventional drugs that should be administered daily or monthly, the drug administration effect can be continuously maintained for one week to three months. In addition, the drug administration effect is maintained for a long time and, simultaneously, microparticles are prepared so as to have the average diameter of a fixed micro-size, and thus an effective drug concentration can be constantly maintained by controlling the release of the drug from the microparticles, and a foreign body sensation and pain can be reduced during drug administration since microparticles having a uniform size are included during application as an injectable drug.

The present invention relates to extended release microparticles comprising a drug, and a preparation method therefor, and when the extended release microparticles comprising a drug are administered in order to replace conventional drugs that should be administered daily or monthly, the drug administration effect can be continuously maintained for one week to three months. In addition, the drug administration effect is maintained for a long time and, simultaneously, microparticles are prepared so as to have the average diameter of a fixed micro-size, and thus an effective drug concentration can be constantly maintained by controlling the release of the drug from the microparticles, and a foreign body sensation and pain can be reduced during drug administration since microparticles having a uniform size are included during application as an injectable drug.

Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof.

Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof.

Disclosed herein is a use of an adenosine triphosphate (ATP) binding cassette (ABC) transporter peptide inhibitor HX-12C. This disclosure also discloses a method of treating a tumor with multidrug resistance mediated by the ABC transporter using a combination of the peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug. Moreover, this disclosure also provides a composition for treating a tumor with multidrug resistance mediated by an ABC transporter, consisting of the peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug.